Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
33
Frequently Asked Questions
What is Market Cap of Cardiff Oncology Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Cardiff Oncology Inc market cap is $135.71M.
What is the 52-week high for Cardiff Oncology Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Cardiff Oncology Inc 52 week high is $5.64 as of September 12, 2025.
What is the 52-week low for Cardiff Oncology Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Cardiff Oncology Inc 52 week low is $1.90 as of September 12, 2025.
What is Cardiff Oncology Inc stock price today?
Cardiff Oncology Inc stock price today is $2.08.
What was Cardiff Oncology Inc stock price yesterday?
Cardiff Oncology Inc stock price yesterday was $2.04.
What is the PE ratio of Cardiff Oncology Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Cardiff Oncology Inc’s P/E ratio is -2.32.
What is the Price-to-Book ratio of Cardiff Oncology Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Cardiff Oncology Inc P/B ratio is 2.3157.
What is the 50-day moving average of Cardiff Oncology Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Cardiff Oncology Inc 50-day moving average is $2.96.